XCL1 and neoplasm: This is in line with that CD8+ effector T cells continue to engage in antigen specific interactions, driving further proliferation and cytokine release.29 The NK_02_XCL1 cells expressed high levels of NKG7, GNLY and XCL1 (Supplementary Fig. 6a), which are crucial for recruiting DCs to enhance anti-tumor immunity.30 Conversely, the decreased fraction of Mo_01_CD14, a classical inflammatory monocyte cluster (Supplementary Fig. 6a) associated with tumor progression and immunosuppression,31,32 suggested a shift towards less tumor-promoting activity after UCB infusion.